Recent advances in antimalarial drug development
- 12 May 2006
- journal article
- review article
- Published by Wiley in Medicinal Research Reviews
- Vol. 27 (1), 65-107
- https://doi.org/10.1002/med.20062
Abstract
Malaria caused by protozoa of the genus Plasmodium, because of its prevalence, virulence, and drug resistance, is the most serious and widespread parasitic disease encountered by mankind. The inadequate armory of drugs in widespread use for the treatment of malaria, development of strains resistant to commonly used drugs such as chloroquine, and the lack of affordable new drugs are the limiting factors in the fight against malaria. These factors underscore the continuing need of research for new classes of antimalarial agents, and a re‐examination of the existing antimalarial drugs that may be effective against resistant strains. This review provides an in‐depth look at the most significant progress made during the past 10 years in antimalarial drug development. © 2006 Wiley Periodicals, Inc. Med Res Rev, 27, No. 1, 65–107, 2007Keywords
This publication has 198 references indexed in Scilit:
- 3D QSAR studies on antimalarial alkoxylated and hydroxylated chalcones by CoMFA and CoMSIAEuropean Journal of Medicinal Chemistry, 2004
- Artemisinins target the SERCA of Plasmodium falciparumNature, 2003
- Genome sequence of the human malaria parasite Plasmodium falciparumNature, 2002
- Hurrah for Genome Projects!Parasitology Today, 2000
- Strategies for the prevention of antimalarial drug resistance: Rationale for combination chemotherapy for malariaParasitology Today, 1996
- Haemozoin: Identification and quantificationParasitology Today, 1996
- Second-generation antimalarial endoperoxidesParasitology Today, 1996
- New Antimalarials A Risk-Benefit AnalysisDrug Safety, 1995
- Clinical Pharmacokinetics in the Treatment of Tropical DiseasesClinical Pharmacokinetics, 1994
- Reversal of Chloroquine Resistance in Malaria Parasite Plasmodium falciparum by DesipramineScience, 1988